

**HOMEOPATHY IN APLASTIC ANEMIA: A CRITICAL NARRATIVE REVIEW OF
CLINICAL EVIDENCE, INDIVIDUALIZED ADVANCED HOMEOPATHY TREATMENT**

Prof. (Dr.) Ashvini Kumar Dwivedi, BHMS, MD (Homoeopathy), PhD, MBA (HR), MA (Yoga), MA (Psychology), FHCH (UK)

Professor & Head, Department of Physiology & Biochemistry, S.K.R.P. Gujarati Homoeopathic Medical College,
Hospital & Research Centre, Indore, Madhya Pradesh, India.

Director, Advanced Homeo Health Centre & Homoeopathic Medical Research Pvt. Ltd., Indore, India

Executive Council Member, Devi Ahilya Vishwavidyalaya (DAVV), Indore, India

Editor, *Sehat Evam Surat*, Hindi Health Magazine.



***Corresponding Author: Prof. (Dr.) Ashvini Kumar Dwivedi, BHMS, MD (Homoeopathy), PhD, MBA (HR), MA (Yoga), MA (Psychology), FHCH (UK)**

Professor & Head, Department of Physiology & Biochemistry, S.K.R.P. Gujarati Homoeopathic Medical College, Hospital & Research Centre, Indore, Madhya Pradesh, India.

DOI: <https://doi.org/10.5281/zenodo.23031368>

How to cite this Article: Prof. Dr. Ashvini Kumar Dwivedi, BHMS, MD (Homoeopathy), PhD, MBA (HR), MA (Yoga), MA (Psychology), FHCH (UK). (2026). Homeopathy In Aplastic Anemia: A Critical Narrative Review of Clinical Evidence, Individualized Advanced Homeopathy Treatment. European Journal of Pharmaceutical and Medical Research, 13(10), 1-9. This work is licensed under Creative Commons Attribution 4.0 International license.



Article Received on 25/08/2026

Article Revised on 15/09/2026

Article Published on 01/10/2026

ABSTRACT

Background: Aplastic anaemia (AA) is a potentially life-threatening bone-marrow-failure disorder characterized by hypocellular bone marrow and peripheral pancytopenia. Severe and very severe forms require prompt specialist management because infection, haemorrhage and profound anaemia may result in substantial morbidity and mortality. Advanced homeopathy treatment may be best Contemporary management includes supportive transfusion and antimicrobial care, immunosuppressive therapy and hematopoietic stem-cell transplantation according to disease severity, age, donor availability and other clinical factors. **Objective:** To critically review the available literature concerning homeopathy in aplastic anaemia, with particular emphasis on published clinical observations and case-based evidence, including the author's previously published work, and to identify priorities for future scientifically rigorous investigation. **Methods:** A targeted literature review was undertaken using publicly accessible biomedical and scholarly sources. Literature concerning the diagnosis and treatment of aplastic anaemia, complementary and homeopathic approaches, and the author's publications relating to aplastic anaemia and haematological disorders was examined. Evidence was categorized according to study design, clinical relevance and susceptibility to bias. Contemporary haematology guidelines and major clinical trials were considered as the reference standard for established management. **Results:** The literature directly evaluating homeopathy in aplastic anaemia is extremely limited and consists predominantly of case reports, observational reports and descriptive clinical publications. The author's publications include a case study of aplastic anaemia, an article describing homeopathic management of aplastic anaemia in adults, and a subsequent publication concerning red-cell aplasia and individualized homeopathic treatment. These reports describe haematological improvement in individual patients, but their uncontrolled designs prevent causal attribution to homeopathic treatment. A recent independent case report has likewise described complementary homeopathic treatment alongside conventional therapy in a patient with severe aplastic anaemia, but this evidence remains hypothesis-generating rather than confirmatory. **Conclusion:** Published clinical observations justify further investigation of individualized homeopathic care as a possible complementary intervention in selected patients with aplastic anaemia, but they do not establish homeopathy as a stand-alone treatment or cure. The principal research priority should be prospective, ethically approved, independently monitored studies incorporating objective haematological endpoints, transfusion requirements, infection burden, quality of life, treatment-related adverse events and long-term clonal outcomes. Until such evidence becomes available, homeopathy should not replace evidence-based haematological treatment.

KEYWORDS: Aplastic Anaemia; Bone Marrow Failure; Pancytopenia; Homeopathy; Individualized Medicine; Complementary Medicine; Haematology; Immunosuppressive Therapy; Hematopoietic Stem-Cell Transplantation; Integrative Medicine.

1. INTRODUCTION

Aplastic anaemia is a potentially fatal disorder characterized by failure of haematopoiesis, hypocellular bone marrow and reduction of circulating blood-cell lineages. Acquired AA is frequently associated with immune-mediated destruction or suppression of hematopoietic stem and progenitor cells. Establishing the diagnosis requires careful exclusion of inherited bone-marrow-failure syndromes, hypoplastic myelodysplastic syndromes, paroxysmal nocturnal haemoglobinuria and other causes of pancytopenia.

The clinical spectrum ranges from non-severe disease to severe and very severe aplastic anaemia. Disease severity, age, comorbidity, infection risk, transfusion dependence and donor availability substantially influence treatment decisions.


Modern management has evolved considerably. Current international guidance emphasizes specialist diagnostic evaluation, supportive transfusion and antimicrobial management, followed by either allogeneic hematopoietic stem-cell transplantation or immunosuppressive therapy in appropriate patients.

Contemporary immunosuppressive treatment commonly incorporates horse ant thymocyte globulin and ciclosporin, with entomophagy increasingly incorporated into front-line treatment strategies.

The introduction of entomophagy illustrates the importance of rigorous prospective investigation. In a randomized phase 3 study, adding entomophagy to horse ant thymocyte globulin and ciclosporin increased the proportion of patients achieving complete hematologic response at three months compared with immunosuppressive therapy alone.

Against this background, complementary medical approaches continue to be explored by some patients and practitioners. Homeopathy is individualized according to the totality of symptoms and other clinical characteristics. However, the evidence base for homeopathy in life-threatening haematological disorders remains particularly limited.

The distinction between a promising clinical observation and demonstrated therapeutic efficacy is therefore critical.



Representative Images

Rationale for the Present Review

The author's clinical and academic work has included anaemia, sickle-cell disease, aplastic anaemia, red-cell aplasia and other haematological disorders.

Several publications from the author's group have specifically addressed aplastic anaemia and related disorders. These publications provide a clinically relevant starting point for developing a more rigorous research program.

The purpose of the present review is therefore not to claim that existing observations establish efficacy. Rather, it is to:

1. consolidate the available literature;
2. examine the author's published work in the context of current haematological knowledge;
3. identify methodological strengths and weaknesses;
4. distinguish hypothesis-generating evidence from confirmatory evidence;
5. propose a scientifically defensible framework for future clinical research.

Contemporary Understanding of Aplastic Anaemia Pathophysiology

Acquired aplastic anaemia is commonly considered an immune-mediated bone-marrow-failure syndrome in which autoreactive immune mechanisms contribute to depletion or suppression of hematopoietic stem and progenitor cells.

This understanding is supported by the clinical response of many patients to immunosuppressive therapy and by experimental evidence demonstrating immune-mediated hematopoietic injury.

The disease should nevertheless not be viewed as biologically homogeneous. Genetic predisposition, somatic mutations, immune mechanisms, marrow microenvironment, clonal evolution and the presence of PNH clones may influence clinical phenotype and prognosis.

DIAGNOSIS

Diagnosis should be based on an integrated assessment comprising:

- complete blood count;
- reticulocyte count;
- peripheral blood examination;
- bone-marrow aspirate and biopsy;
- cytogenetic and molecular investigations where indicated;
- evaluation for PNH;
- viral and infectious evaluation;
- assessment for inherited bone-marrow-failure syndromes where clinically appropriate;
- exclusion of hypoplastic myelodysplastic syndrome and other mimics.

Modern diagnostic algorithms emphasize the importance of distinguishing acquired AA from inherited marrow-failure disorders and hypoplastic myelodysplasia before definitive treatment is selected.

Established Treatment of Aplastic Anaemia

Treatment depends on severity and patient characteristics.

Current guidelines identify allogeneic hematopoietic stem-cell transplantation and immunosuppressive therapy as the principal disease-modifying approaches for acquired AA. Supportive care remains essential throughout treatment.

For suitable patients with severe or very severe AA, treatment selection considers age, performance status, donor availability and institutional expertise.

Horse ant thymocyte globulin combined with ciclosporin has historically constituted a major immunosuppressive platform. Entomophagy has subsequently provided an additional strategy for improving hematologic response.

These developments are important when evaluating complementary interventions because any investigational treatment must be studied in addition to, rather than instead of, appropriate standard care in patients with serious disease.

A comprehensive appraisal of the available literature indicates that the role of **Homoeopathy in Aplastic Anaemia (AA), Pancytopenia, and related Bone Marrow Disorders remains an emerging area of clinical research**, with the published evidence to date consisting predominantly of case reports, observational studies, and descriptive clinical reports. Nevertheless, the clinical observations reported by **Dr. A. K. Dwivedi, Advanced Homeo Health Centre, Indore**, merit particular consideration. His therapeutic approach involves individualized Homoeopathic prescribing based upon the patient's clinical symptomatology, disease presentation, and serial haematological investigations, with the use of **50-millesimal (LM) potencies**.

In a substantial number of patients observed in his clinical practice, treatment has been associated with **progressive improvement in haemoglobin concentration, platelet counts, total leukocyte counts, and other relevant haematological parameters**. Of particular clinical interest, several patients demonstrated a reduction in their requirement for blood and platelet transfusions, while in some cases transfusion support could subsequently be discontinued and was not required again during the documented follow-up period. Patients also reported improvement in **general well-being, fatigue, functional capacity, and overall clinical status**. Taken collectively, these observations raise the possibility that individualized Homoeopathic treatment may have a **potential therapeutic and supportive role**

in the clinical management of Aplastic Anaemia and related bone-marrow disorders.

At the same time, these findings should be interpreted within the methodological limitations of observational clinical evidence. Hematological improvement cannot, on the basis of observational data alone, be unequivocally attributed to the Homoeopathic intervention, since other factors—including delayed effects of previous treatment, resolution of precipitating factors, management of infections or inflammation, supportive care, transfusion-related changes, and the natural temporal variability of the disease—may contribute to clinical improvement. Recognition of these potential confounding factors does not diminish the clinical relevance of the observations; rather, it underscores the importance of subjecting them to rigorous prospective scientific evaluation.

The consistent documentation of serial hematological parameters, clinical improvement, changes in transfusion requirements, and longitudinal patient outcomes provides a valuable foundation for further investigation. Future research should therefore incorporate prospective study designs, standardized case documentation, long-term follow-up, predefined hematological outcome measures, systematic assessment of transfusion dependence, appropriate comparator groups, and well-designed controlled clinical trials. Such studies would be essential to determine the magnitude, reproducibility, and clinical significance of the observed therapeutic effects.

While the existing evidence should appropriately be regarded as preliminary clinical evidence rather than definitive proof of efficacy, the sustained clinical work of Dr. A. K. Dwivedi in the field of Aplastic Anemia, Pancytopenia, and Bone Marrow Disorders, together with the documented positive clinical outcomes observed in his practice, represents a noteworthy and potentially valuable contribution to this relatively under-investigated area of Homoeopathic research. These observations warrant systematic scientific investigation and may provide a meaningful basis for developing more rigorous evidence concerning the potential role of individualized Homoeopathic care in patients with bone-marrow failure disorders.

Published Work of the Author Relevant to Aplastic Anaemia and Haematological Disorders “A Case Study: Aplastic Anaemia” — 2018

The author's 2018 publication in *Periapex – Indian Journal of Research* presented aplastic anaemia as a clinical case-based investigation.

Its principal importance is as an early clinical observation documenting the possibility of haematological changes during homeopathic care.

However, as with other single-case reports, causal inference is limited.

The appropriate interpretation is therefore that the case provides a **clinical signal worthy of further investigation**, rather than proof of efficacy.

Iron Deficiency Anaemia & Homeopathy Medicines” — 2019

The author's 2019 publication in the *Indian Journal of Applied Research* examined homeopathic medicines in iron-deficiency anaemia.

Iron-deficiency anaemia differs fundamentally from aplastic anaemia.

Iron deficiency is primarily a disorder of iron availability and erythropoiesis, whereas AA represents bone-marrow failure involving one or more hematopoietic lineages.

Consequently, observations in iron-deficiency anaemia cannot be directly extrapolated to aplastic anaemia.

Nevertheless, the publication demonstrates the author's longstanding research interest in haematological disorders and anaemia.

“Homeopathy – A Cure to Fatal Aplastic Anaemia” — 2022

The author's 2022 publication in the *International Journal of Scientific Research* specifically addressed aplastic anaemia.

From the perspective of contemporary publication standards, the term “cure” should be interpreted cautiously unless supported by rigorous objective evidence, long-term follow-up and exclusion of alternative explanations.

For a new high-level publication, it would be preferable to use terminology such as:

“Clinical and haematological improvement,”

“Haematological response,”

or

“Complementary therapeutic potential.”

This terminology is more compatible with evidence-based publication standards.

“Observational Study: Aplastic Anaemia & Homeopathic for Adults” — 2024

The author subsequently published an observational study specifically addressing adult aplastic anaemia.

The article describes AA as a bone-marrow disorder and discusses homeopathic management with case studies.

This publication is particularly relevant to the present review because it represents a transition from an isolated case-based approach toward an observational clinical framework.

Nevertheless, the absence of randomization, a contemporaneous control group and blinded outcome assessment limits the strength of causal conclusions.

“Red Blood Cell (RBC) Aplasia and its Homeopathic Medicines with Integrated Clinical Management” — 2025

The author's 2025 publication examined red-cell aplasia and individualized homeopathic management.

The article describes pure red-cell aplasia as a rare condition involving marked reduction of erythroid precursors and discusses congenital and acquired causes. It also presents representative clinical cases from the Advanced Homoeo Health Centre, Indore.

This work is relevant because pure red-cell aplasia and aplastic anaemia occupy overlapping but distinct areas of haematological pathology.

The distinction should be maintained carefully in future research because improvement in erythropoiesis alone does not establish reversal of global marrow aplasia.

Other Relevant Haematological Research by the Author

The author's research portfolio also includes:

“Symptomatic Relief in Sickle Cell Disease Patients by Homeopathy Medicines.”

The publication describes symptomatic improvement in patients with sickle-cell disease and was published in the *International Journal of Homoeopathic Sciences* in 2022; a related publication subsequently appeared in *Advancements in Homeopathic Research*.

Although sickle-cell disease and aplastic anaemia are biologically distinct, this work demonstrates the author's continuing research interest in haematological disease and symptom-oriented clinical outcome.

Summary of the Author's Relevant Publications

Year	Publication	Study type	Relevance
2018	<i>A Case Study: Aplastic Anaemia</i>	Case report	Directly relevant
2019	<i>Iron Deficiency Anaemia & Homeopathy Medicines</i>	Clinical/descriptive	Related haematological condition
2022	<i>Homeopathy – A Cure to Fatal Aplastic Anaemia</i>	Case/clinical report	Directly relevant
2022	<i>Symptomatic Relief in Sickle Cell Disease Patients by Homeopathy Medicines</i>	Clinical report	Related haematological research
2024	<i>Observational Study: Aplastic Anaemia & Homeopathic for Adults</i>	Observational study	Directly relevant
2025	<i>Red Blood Cell Aplasia and its Homeopathic Medicines with Integrated Clinical Management</i>	Clinical/case-based report	Closely related marrow disorder

The 2024 and 2025 publications are particularly important because they extend the author's work beyond a single case toward broader clinical observation.

Independent Literature

A recent 2026 case report described complementary homeopathic treatment in a 69-year-old woman with severe aplastic anaemia receiving conventional treatment. The report described individualized *Phosphorus* along with *Lecithin* and *Ferrum metallicum* and reported haematological improvement over two years.

This report is relevant because it supports the existence of continuing clinical interest in complementary homeopathic approaches.

However, it also illustrates the principal methodological problem in this field: because homeopathy was administered alongside conventional treatment, the contribution of homeopathy cannot be isolated.

Therefore, such evidence should be considered hypothesis-generating.

Evidence Hierarchy and Critical Appraisal

The current evidence can be conceptualized as follows:

Level 1 — Established evidence

Randomized trials and international guidelines supporting transplantation, immunosuppressive therapy and contemporary pharmacological approaches.

Level 2 — Observational evidence

Clinical cohorts and observational studies evaluating outcomes without randomization.

Level 3 — Case reports and case series

The majority of currently identified homeopathic literature concerning AA belongs here.

Level 4 — Mechanistic hypotheses

Proposed biological explanations that have not yet been sufficiently validated in human clinical studies.

The evidence currently available for homeopathy in AA does **not** reach the evidentiary level required to establish efficacy equivalent to established disease-modifying treatments.

This conclusion does not mean that clinical observations should be ignored. Rather, it defines the appropriate next step: rigorous investigation.

Why a New Research Program Is Justified

Three observations justify further investigation.

First, AA is biologically complex and heterogeneous.

Second, patients frequently seek complementary interventions during prolonged treatment and recovery.

Third, the existing homeopathic literature contains clinical observations suggesting that systematic investigation may be worthwhile, while remaining insufficient to establish efficacy.

A scientifically appropriate research program should therefore move beyond retrospective case narratives.

Proposed Model for Future Clinical Research

A prospective multicentre observational cohort would be an appropriate initial step.

Population

Patients with objectively diagnosed acquired aplastic anaemia, categorized according to established severity criteria.

Intervention

Individualized homeopathic treatment provided by qualified practitioners.

Conventional care

Patients should continue standard haematological management according to current guidelines.

Primary outcomes

The following objective endpoints should be prospectively recorded:

1. Haemoglobin concentration;
2. absolute neutrophil count;
3. platelet count;
4. reticulocyte count;
5. transfusion independence;
6. bone-marrow cellularity;
7. infection frequency;
8. clinically significant bleeding;
9. hospitalization;
10. survival.

Secondary outcomes

- fatigue;
- health-related quality of life;
- functional status;
- treatment burden;
- patient-reported outcomes;
- adverse events;
- medication adherence.

Long-term outcomes

Because AA carries risks of relapse and clonal evolution, follow-up should ideally include:

- relapse;
- PNH clone evolution;
- myelodysplastic transformation;
- acute myeloid leukaemia;

- overall survival;
- event-free survival.

Contemporary haematology literature emphasizes the importance of long-term surveillance because clonal evolution remains a clinically relevant concern.

Proposed Research Design for a Future Controlled Trial

The strongest future design would be a randomized, controlled, pragmatic clinical trial.

Arm A

Standard haematological treatment + individualized homeopathic care.

Arm B

Standard haematological treatment + control/sham intervention or usual supportive care.

Randomization should occur only after diagnostic confirmation and assessment by a haematology team.

The study should be independently monitored, prospectively registered and approved by an institutional ethics committee.

Objective Outcome Measurement

An important weakness of previous case-based literature is dependence on narrative clinical improvement.

Future research should prioritize objective endpoints.

For example

Haematological response

- Hb improvement;
- ANC improvement;
- platelet recovery;
- reticulocyte response.

Clinical response

- reduction in transfusion requirement;
- reduction in hospitalization;
- reduction in infection episodes;
- reduction in clinically significant bleeding.

Biological response

- marrow cellularity;
- cytogenetic stability;
- PNH clone;
- molecular findings where appropriate.

Patient-centred response

- validated quality-of-life instruments;
- fatigue scales;
- functional status.

This would substantially strengthen the evidentiary value of the research.

Safety and Ethical Considerations

Aplastic anaemia is potentially life-threatening.

Consequently, research involving complementary medicine must establish strict safety boundaries.

Homeopathy should not delay:

- haematology referral;
- diagnostic bone-marrow evaluation;
- blood transfusion when clinically indicated;
- antimicrobial treatment;
- immunosuppressive therapy;
- stem-cell transplantation when indicated;
- Emergency management of bleeding or infection.

This is consistent with the principle that complementary interventions should not replace established treatment for serious disease. The National Centre for Complementary and Integrative Health similarly advises against replacing proven conventional treatment with homeopathy.

The Aplastic Anaemia and MDS International Foundation also states that there is currently no complementary or alternative therapy proven to effectively treat bone-marrow failure.

These statements should be acknowledged explicitly in a high-quality publication rather than omitted.

DISCUSSION

The literature reviewed here presents an interesting but immature field.

The author's publications provide a sequence of clinical observations spanning approximately eight years, from an early case report in 2018 through observational work in 2024 and a related investigation of red-cell aplasia in 2025.

The most important scientific contribution of these publications may therefore be their role in generating a research hypothesis.

At present, it would be scientifically premature to conclude that homeopathy independently reverses aplastic anaemia.

However, it is equally inappropriate to regard every clinical observation as meaningless without investigation.

The appropriate scientific response is controlled observation.

The field now requires:

- larger patient cohorts;
- standardized diagnostic criteria;
- transparent case definitions;
- prospective follow-up;
- objective haematological endpoints;
- predefined statistical analysis;
- independent adjudication;

- registration of protocols;
- reporting of negative as well as positive outcomes;
- and long-term safety surveillance.

Integrative Clinical Perspective

A potentially useful research question is not necessarily: "Can homeopathy replace conventional treatment in aplastic anaemia?"

Such a question would be clinically inappropriate given the life-threatening nature of severe AA and the absence of adequate evidence.

A more scientifically meaningful question is:

"Does individualized homeopathic care, when added to appropriate standard haematological management, provide measurable benefits in patient-reported outcomes, supportive-care burden, haematological recovery or quality of life?"

This question is testable.

It also permits appropriate ethical protection of patients.

Strengths of the Present Review

The present review has several strengths:

1. It integrates the author's longitudinal publications concerning AA and related haematological disorders.
2. It places homeopathic observations within the contemporary haematological treatment framework.
3. It distinguishes case-based evidence from controlled clinical evidence.
4. It emphasizes objective haematological outcomes.
5. It proposes a reproducible pathway for future clinical research.
6. It explicitly addresses safety and ethical considerations.

LIMITATIONS

This review has important limitations.

First, the literature directly evaluating homeopathy in AA is very small.

Second, most available reports are observational or case based.

Third, the author's own publications constitute a substantial portion of the directly relevant literature identified in this review, introducing potential author-related publication bias.

Fourth, several reports lack the methodological characteristics required to establish causality.

Fifth, the present manuscript is a critical narrative review rather than a registered systematic review or meta-analysis. Consequently, no quantitative pooled estimate of treatment effect is presented.

A future systematic review should search PubMed/MEDLINE, Embase, Scopus, Web of Science, CENTRAL and relevant complementary-medicine databases using a prespecified protocol and PRISMA methodology.

Future Research Priorities

The following research agenda is proposed:

Priority 1

Establish a prospective registry of AA patients receiving complementary homeopathic care.

Priority 2

Standardize diagnostic and severity criteria.

Priority 3

Record complete serial CBC, reticulocyte, marrow and transfusion data.

Priority 4

Document every conventional treatment received concurrently.

Priority 5

Record individualized homeopathic prescriptions and changes over time.

Priority 6

Use validated quality-of-life instruments.

Priority 7

Perform independent outcome assessment.

Priority 8

Develop multicentre prospective cohorts.

Priority 9

Proceed to randomized controlled trials only after adequate feasibility and safety data.

Priority 10

Maintain long-term surveillance for relapse and clonal evolution.

CONCLUSION

Aplastic Anemia remains a serious disorder of bone-marrow failure requiring accurate diagnosis, careful hematological evaluation, specialist supervision, and timely, evidence-based management. Within this clinical context, the emerging observations concerning individualized Homoeopathic care merit systematic scientific attention.

Although the published literature on Homoeopathy in Aplastic Anemia remains relatively limited and is predominantly represented by case reports, observational studies, and descriptive clinical publications, the author's clinical publications from 2018, 2022, 2024, and 2025 provide a progressive body of clinical observations in patients with Aplastic Anemia and related hematological disorders. The documented observations—including changes in hemoglobin, platelet counts, leukocyte parameters, clinical symptoms, general well-being, and, in several patients, a reduction or discontinuation of transfusion requirements—provide an encouraging basis for further investigation.

These clinical findings should be regarded as promising preliminary evidence rather than definitive proof of therapeutic efficacy. Importantly, however, the consistency of the reported clinical observations and their longitudinal documentation suggest that individualized Homoeopathic care may warrant serious scientific evaluation as a potential complementary therapeutic approach within an appropriately supervised, multidisciplinary framework.

The central proposition emerging from these observations is therefore not that Homoeopathy should replace established hematological treatment, but that its potential clinical contribution deserves rigorous investigation rather than premature dismissal. Future research should employ prospective study designs, standardized case documentation, objective and serial hematological outcomes, systematic assessment of transfusion requirements, appropriate comparator groups, transparent reporting, and long-term follow-up.

The progression from individual clinical observations to independently reproducible scientific evidence represents the next essential step. Such research may help clarify the potential role of individualized Homoeopathic treatment in the comprehensive management of Aplastic Anemia and contribute to the development of a stronger evidence base for integrative approaches to bone-marrow failure disorders.

DECLARATIONS**Ethical approval**

Not applicable to this narrative literature review.

Patient consent

Not applicable.

Conflict of interest

The author is the author of several publications discussed in this review. This relationship should be explicitly declared to the journal.

Funding

No external funding was declared for preparation of this review.

Author contribution

The author conceived the review, identified the relevant clinical research theme, interpreted the literature and prepared the manuscript.

Data availability

No new patient-level dataset was generated for this review.

BIOGRAPHY

Dr. A. K. Dwivedi, BHMS (Gold Medallist), MD, MBA, Ph.D. has been a Registered Homeopaths for over 30 years. He is a Professor & HOD: Department of Physiology S.K.R.P. Gujarati Homoeopathic Medical

College, Indore. He is a Member of Executive Council, Devi Ahilya Vishwavidyalaya Indore, MP, INDIA, he is also a Member Scientific Advisory Board (CCRH) Ministry of Ayush, Govt of India. Member, Scientific Advisory Committee (NEAH) Shilong Meghalaya, Ministry of Ayush, Govt. of India, Member Academic Board Madhya Pradesh Medical Science University, Jabalpur MP (India). DIRECTOR, & CEO Advanced Homeo Health Centre & Homeopathic Medical Research Pvt.Ltd. Indore, Madhya Pradesh, India, EDITOR, "SEHAT EVAM SURAT"(Hindi Monthly Medical Magazine).

REFERENCES

1. Babushok DV, DeZern AE, de Castro CM, et al. Modified Delphi panel consensus recommendations for management of severe aplastic anemia. *Blood Advances*, 2024; 8(15): 3946-3960. doi:10.1182/bloodadvances.2023011642.
2. Kulasekararaj A, Cavenagh J, Dokal I, et al. Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline. *Br J Haematol.*, 2024; 204(3): 784-804. doi:10.1111/bjh.19236.
3. DeZern AE, Churpek JE. Approach to the diagnosis of aplastic anemia. *Blood Advances*, 2021. doi:10.1182/bloodadvances.2021004345.
4. Onishi Y. Aplastic anemia: history and recent developments in diagnosis and treatment. *Int J Hematol.*, 2024; 119(3): 217-219. doi:10.1007/s12185-024-03715-1.
5. Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. *N Engl J Med.*, 2017; 376(16): 1540-1550. doi:10.1056/NEJMoa1613878.
6. Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia. *N Engl J Med.* doi:10.1056/NEJMoa2109965.
7. Dwivedi AK. A Case Study: Aplastic Anaemia. *Paripex – Indian Journal of Research*, 2018; 7(6).
8. Dwivedi AK. Iron Deficiency Anaemia & Homeopathy Medicines. *Indian Journal of Applied Research*. 2019; 9(12).
9. Dwivedi AK. Homeopathy – A Cure to Fatal Aplastic Anemia. *International Journal of Scientific Research*, 2022. doi:10.36106/ijsr.
10. Dwivedi AK. Symptomatic relief in sickle cell disease patients by homeopathy medicines. *International Journal of Homoeopathic Sciences*, 2022; 6(4): 242-243. doi:10.33545/26164485.2022.v6.i4d.666.
11. Dwivedi AK. Observational study: Aplastic anemia & homeopathic for adults. *International Journal of Homoeopathic Sciences*, 2024; 8(2): 112-114. doi:10.33545/26164485.2024.v8.i2b.1128.
12. Dwivedi AK. Red blood cell (RBC) aplasia and its homeopathic medicines with integrated clinical management. *International Journal of Homoeopathic Sciences*, 2025; 9(3): 1009-1011. doi:10.33545/26164485.2025.v9.i3.P.1778.
13. Desai ZP, Desai PH, Shah KV. Complementary use of homeopathy with conventional therapy in aplastic anemia: a case report. *International Research Journal of Multidisciplinary Scope*, 2026; 7(2): 549-556. doi:10.47857/irjms.2026.v07i02.07695.
14. National Center for Complementary and Integrative Health. Homeopathy: What You Need to Know. NCCIH.
15. Aplastic Anemia and MDS International Foundation. Complementary and Alternative Medicine.
16. Young NS. Aplastic anemia. *N Engl J Med.*, 2018; 379(17): 1643-1656.
17. Scheinberg P. Acquired severe aplastic anemia: how medical therapy evolved in the 20th and 21st centuries. *Br J Haematol.*, 2021; 194(6): 954-969